Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, has announced its participation in several key scientific and industry events. The company presented their novel GITR Agonist KROS 101 research at the Society for Immunotherapy of Cancer Spring Scientific Meeting on March 12, 2025, and attended the BIO Europe conference in Milan.
Upcoming events include participation in the Fierce Pharma Engage Business Development meeting in San Diego (April 29-May 1) and a presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago (May 20-June 5). The company recently received research coverage initiation from Maxim Group on March 27.
CEO John Yu highlighted that Phase 2 trials for ENV105 are advancing, while their KROS platform shows promise in cancer immunotherapy, demonstrating the company's commitment to oncology program development and shareholder value creation.
Kairos Pharma (NYSE American: KAPA), un'azienda biofarmaceutica in fase clinica, ha annunciato la sua partecipazione a diversi eventi scientifici e industriali chiave. L'azienda ha presentato la propria ricerca innovativa sul GITR Agonist KROS 101 durante il Meeting Scientifico Primaverile della Society for Immunotherapy of Cancer il 12 marzo 2025 e ha partecipato alla conferenza BIO Europe a Milano.
Tra gli eventi futuri ci sono la partecipazione al meeting Fierce Pharma Engage Business Development a San Diego (dal 29 aprile al 1 maggio) e una presentazione al Meeting Annuale della American Society of Clinical Oncology (ASCO) a Chicago (dal 20 maggio al 5 giugno). L'azienda ha recentemente ricevuto l'inizio della copertura di ricerca da parte di Maxim Group il 27 marzo.
Il CEO John Yu ha evidenziato che i trial di Fase 2 per ENV105 stanno avanzando, mentre la loro piattaforma KROS mostra promettenti risultati nell'immunoterapia contro il cancro, dimostrando l'impegno dell'azienda nello sviluppo di programmi oncologici e nella creazione di valore per gli azionisti.
Kairos Pharma (NYSE American: KAPA), una empresa biofarmacéutica en etapa clínica, ha anunciado su participación en varios eventos científicos e industriales clave. La empresa presentó su novedosa investigación sobre el GITR Agonist KROS 101 en la Reunión Científica de Primavera de la Society for Immunotherapy of Cancer el 12 de marzo de 2025 y asistió a la conferencia BIO Europe en Milán.
Los próximos eventos incluyen la participación en la reunión de Fierce Pharma Engage Business Development en San Diego (del 29 de abril al 1 de mayo) y una presentación en el Encuentro Anual de la American Society of Clinical Oncology (ASCO) en Chicago (del 20 de mayo al 5 de junio). La empresa recibió recientemente el inicio de la cobertura de investigación por parte de Maxim Group el 27 de marzo.
El CEO John Yu destacó que los ensayos de Fase 2 para ENV105 están avanzando, mientras que su plataforma KROS muestra promesas en la inmunoterapia contra el cáncer, demostrando el compromiso de la empresa con el desarrollo de programas oncológicos y la creación de valor para los accionistas.
카이로스 제약(Kairos Pharma) (NYSE American: KAPA)는 임상 단계의 생명공학 회사로 여러 주요 과학 및 산업 행사에 참여한다고 발표했습니다. 회사는 2025년 3월 12일 암 면역 요법 학회(Society for Immunotherapy of Cancer) 봄 과학 회의에서 GITR Agonist KROS 101 연구를 발표했으며, 밀라노에서 열린 BIO 유럽 회의에 참석했습니다.
앞으로의 일정으로는 샌디에이고에서 열리는 Fierce Pharma Engage Business Development 회의(4월 29일부터 5월 1일)와 시카고에서 열리는 미국 임상 종양학회(ASCO) 연례 회의에서의 발표(5월 20일부터 6월 5일)가 포함됩니다. 회사는 3월 27일 Maxim Group으로부터 연구 보도 시작을 받았습니다.
CEO 존 유(John Yu)는 ENV105의 2상 시험이 진행 중이며, KROS 플랫폼이 암 면역 요법에서 가능성을 보이고 있다고 강조하며, 이는 회사의 종양학 프로그램 개발과 주주 가치를 창출하려는 의지를 보여줍니다.
Kairos Pharma (NYSE American: KAPA), une entreprise bio-pharmaceutique en phase clinique, a annoncé sa participation à plusieurs événements scientifiques et industriels clés. L'entreprise a présenté sa recherche novatrice sur le GITR Agonist KROS 101 lors de la Réunion Scientifique de Printemps de la Society for Immunotherapy of Cancer le 12 mars 2025 et a assisté à la conférence BIO Europe à Milan.
Les événements à venir incluent la participation à la réunion Fierce Pharma Engage Business Development à San Diego (du 29 avril au 1er mai) et une présentation lors de la Réunion Annuelle de l'American Society of Clinical Oncology (ASCO) à Chicago (du 20 mai au 5 juin). L'entreprise a récemment reçu le début de la couverture de recherche de Maxim Group le 27 mars.
Le PDG John Yu a souligné que les essais de Phase 2 pour ENV105 avancent, tandis que leur plateforme KROS montre des promesses dans l'immunothérapie contre le cancer, démontrant l'engagement de l'entreprise envers le développement de programmes oncologiques et la création de valeur pour les actionnaires.
Kairos Pharma (NYSE American: KAPA), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat seine Teilnahme an mehreren wichtigen wissenschaftlichen und industriellen Veranstaltungen angekündigt. Das Unternehmen präsentierte seine neuartige Forschung zum GITR Agonist KROS 101 auf dem Frühjahrssymposium der Society for Immunotherapy of Cancer am 12. März 2025 und nahm an der BIO Europe-Konferenz in Mailand teil.
Zu den bevorstehenden Veranstaltungen gehören die Teilnahme am Fierce Pharma Engage Business Development Meeting in San Diego (29. April - 1. Mai) und eine Präsentation auf dem Jahrestreffen der American Society of Clinical Oncology (ASCO) in Chicago (20. Mai - 5. Juni). Das Unternehmen erhielt kürzlich am 27. März den Beginn der Forschungsberichterstattung von Maxim Group.
CEO John Yu hob hervor, dass die Phase-2-Studien für ENV105 voranschreiten, während ihre KROS-Plattform vielversprechende Ergebnisse in der Krebsimmuntherapie zeigt, was das Engagement des Unternehmens für die Entwicklung von Onkologieprogrammen und die Schaffung von Aktionärswert unterstreicht.
- None.
- None.
Highlights include:
- March 12, 2025 – Presented at the Society for Immunotherapy of Cancer Spring Scientific Meeting titled, “Novel GITR Agonist KROS 101: A Dual Approach to Boost T Cell Immunity and Alter the Tumor Microenvironment”
-
March 17 to 19 – Participated in the BIO Europe conference in
Milan, Italy
-
April 29 to May 1 – Kairos is slated to participate at the Fierce Pharma Engage Business Development and Licensing Meeting in
San Diego
-
May 20 to June 5 – The American Society of Clinical Oncology (ASCO) has accepted an abstract to be presented at its Annual Meeting in
Chicago
- March 27 – Maxim Group initiates research coverage of Kairos Pharma
"Kairos continues to gain momentum in both the scientific and business communities as we showcase the value of our diverse oncology programs. Our Phase 2 trials for ENV105 are progressing, while our KROS platform continues to demonstrate promising potential in cancer immunotherapy," said John Yu, M.D., CEO of Kairos Pharma. "We remain committed to advancing our developments alongside our partners, sharing our progress with the market, and driving long-term shareholder value."
About Kairos Pharma Ltd.
Based in
CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements as those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential” or “hopes” or the negative of these or similar terms. The reader is cautioned not to rely on these forward-looking statements. If underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kairos Pharma. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including: our expectations regarding the success and/or completion of our Phase 1 and Phase 2 clinical trials; our success in completing newly initiated clinical trials, commence new trials, and obtain regulatory approval following the conclusion of such trials; challenges and uncertainties inherent in product research and development; and the uncertainty regarding future commercial success. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking statements discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us, including those described in Kairos Pharma’s prospectus and our other filings made with the SEC. We are not obligated to publicly update or revise any forward-looking statement, and Kairos Pharma is not required to update any forward-looking statement as a result of new information or future events or developments, except as required by
View source version on businesswire.com: https://www.businesswire.com/news/home/20250327798514/en/
CORE IR
Louie Toma
investors@kairospharma.com
Source: Kairos Pharma, Ltd
FAQ
What scientific conferences is KAPA presenting at in 2025?
What is the current development status of KAPA's ENV105 drug?
What new research did KAPA present about KROS 101?
When did Maxim Group initiate coverage of KAPA stock?
What are the main therapeutic areas KAPA is focusing on?
